The p53 gene is one of the most well studied oncogenes. From our experience and the experience published in the medical literature, the p53 oncogene is mutated or properly expressed in about 60% of all cancers. The p53 gene is the gene that translates into a protein called the p53 protein. When the p53 protein is expressed in a cell that cell is then commited to apoptosis (natural cell death). Much research is underway at our clinic and many other clinics to develope ways to up regulate the p53 gene expression in cancer cells. This can be aided with nutraceutical, but the nutraceuticals still need a functional p53 gene.
Gendicine is a Chinese FDA approved p53 gene therapy that can restore the normal p53 gene function in cancer cells. We use Gendicine at the IAT clinic in a clinical trial for bladder cancer.
We are looking for 30 people with bladder cancer to register for treatment with Gendicine recombinant p53 gene therapy. Please contact us if you are interested in this treatment for Bladder Cancer…Please fill out the client registration form on line.